July 15, 2025

Data from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase I trial demonstrates improved survival in AML patients resistant to standard treatments, highlighting benefits of dual targeting FLT3 and MDM2.

Dual inhibition of FLT3-ITD and MDM2 significantly induced apoptosis in resistant AML cell lines.
Q/M treatment showed 40% complete response in relapsed AML patients, indicating viable clinical application.
Preclinical studies utilized xenograft models and single-cell proteomic analysis for robust findings.
Combining FLT3 and MDM2 targeting presents a promising strategy for enhancing treatment outcomes in AML.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I trial demonstrates improved survival in AML patients resistant to standard treatments, highlighting benefits of dual targeting FLT3 and MDM2.